Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer

NCT00351858 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
40
Enrollment
INDUSTRY
Sponsor class

Stopped company focus on other projects

Conditions

Interventions

Sponsor

Neovii Biotech